moxifloxacin has been researched along with anacetrapib in 1 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (anacetrapib) | Trials (anacetrapib) | Recent Studies (post-2010) (anacetrapib) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 179 | 33 | 143 |
| Protein | Taxonomy | moxifloxacin (IC50) | anacetrapib (IC50) |
|---|---|---|---|
| Cholesteryl ester transfer protein | Homo sapiens (human) | 0.0343 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Farmer, HF; Johnson-Levonas, AO; Lai, E; Larson, P; Lauring, B; Li, XS; Liu, Y; Moreau, A; Wagner, JA | 1 |
1 trial(s) available for moxifloxacin and anacetrapib
| Article | Year |
|---|---|
Single therapeutic and supratherapeutic doses of anacetrapib, a cholesteryl ester transfer protein inhibitor, do not prolong the QTcF interval in healthy volunteers.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anticholesteremic Agents; Arrhythmias, Cardiac; Cholesterol Ester Transfer Proteins; Cohort Studies; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drugs, Investigational; Electrocardiography; Female; Fluoroquinolones; Heart; Humans; Male; Middle Aged; Models, Biological; Moxifloxacin; Oxazolidinones; Topoisomerase II Inhibitors; Young Adult | 2014 |